In order to better help the clinic select targeted drugs, Genecast has released the Genecast Lung and Genecast CRC.

Genecast Lung is a precision medicine guidance product for patients with non-small cell lung cancer. It takes peripheral blood or tissue as a sample and NGS for genetic testing. It predicts the sensitivity of targeted drugs with clinical evidence, thus guiding patients to choose tumor-targeting drugs. 

Genecast Lung is a precision medicine guidance product for patients with colorectal cancer. It takes the same sample and detection platform as Genecast Lung does. The two products launched by Genecast have the following three characteristics.

More professional—the two products strictly follow NCCN and important clinical trials medicine guide to provide a more professional personalized treatment planning.

Genecast Lung, Genecast CRC provide professional personalized medicine guidance based on evidence.

Genecast Lung, Genecast CRC include FDA and CFDA approved targeted medicine and their evidence used for non-small cell lung cancer and colorectal cancer. They also cover targeted drugs and evidence that have been validated in clinical studies.

The gene were detected by Genecast Lung, Genecast CRC include 8 gene for the treatment of non-small cell lung cancer (including EGFR, ALK, ROS1, MET, RET, ERBB2, BRAF, KRAS ) and 6 genefor the treatment of colorectal cancer (including KRAS, NRAS, BRAF, PIK3CA, ERBB2, and irinotecan toxicity-related UGT1A1) recommended by NCCN guidelines. Through gene detection and evidence-based solution, more professional medication guidance will be given.

More comprehensive—the two drugs comprehensively test the hotspots, rare and unknown mutation loci without missing any targeted therapeutic opportunities. This feature mainly comes from the detection strength of Genecast.

Genecast Lung, Genecast CRC employ the SeqCap with a more uniform trapping efficiency to fully detect hotspots, rare and unknown mutation loci, not missing drug-related information.

The testing process of Genecast Lung, Genecast CRC undergoes strict quality control to ensure the test data is highly accurate and no valuable treatment information is missing.

In the process of testing, Genecast Lung, Genecast CRC use negative and positive standards as external control indicators and independent standards as internal control indicators, thereby minimizing the probability of false positives and false negatives, and greatly improving the accuracy of the test without missing any targeted treatment opportunities. This method also avoids the misuse of targeted drugs.

More efficient— one-time parallel detection of multiple gene loci saves more time with less sample consumption.

Genecast Lung, Genecast CRC adopt NGS to break the barriers of traditional detecting technology and realize parallel detection on multiple gene loci at one time, thereby saving sample consumption.

Genecast Lung, Genecast CRC, two precision medicine guidance products specially created for patients with non-small cell lung cancer and colorectal cancer, will keep the professional Genecast spirit and provide better precision medicine guidance service for clinic.